Erratum: Breast Cancer: A Review for the general surgeon (JAMA Surgery (2013) 148:10 (971-979) DOI: :10.1001/jamasurg.2013.3393);Breast cancer: A review for the general surgeon

JAMA Surgery

Volumn 148, Issue 10, 2013, Pages 971-979

  Matsen, Cindy B ^a   Neumayer, Leigh A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CLINICAL PRACTICE; GENERAL SURGERY; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURGEON;

EID: 84886403168     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2013.5153     Document Type: Erratum

References (130)

1. American Cancer Society. Breast cancer: facts & figures 2011-2012. http://www.cancer.org/acs /groups/content/@epidemiologysurveilance /documents/document/acspc-030975.pdf. Accessed October 11, 2012.
2. Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97(10):715-723.
3. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
4. Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103(12):951-961.
5. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99(23):1782-1792.
6. Banegas MP, Gail MH, LaCroix A, et al. Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat. 2012;132(1):347-353.
7. Vogel VG, Costantino JP, Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727- 2741.
8. Vogel VG, Costantino JP, Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6): 696-706.
9. Wickerham DL. Breast cancer chemoprevention: progress and controversy. Surg Oncol Clin North Am. 2010;19(3):463-473.
10. Oppong BA, King TA. Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park). 2011;25(11):1051-1056; 1058.
11. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw. 2006;4(5):511-522.
12. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-1662.
13. Njiaju UO, Olopade OI. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012;18(5):436-442.
14. Shannon KM, Chittenden A. Genetic testing by cancer site: breast. Cancer J. 2012;18(4):310-319.
15. Bevers TB, Anderson BO, Bonaccio E, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-1096.
16. Brown P. Risk assessment: controversies and management of moderate-to high-risk individuals. Breast J. 2005;11(suppl 1):S11-S19.
17. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.
18. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088-2090.
19. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245-259.
20. Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J. 2011;17(6):492-499.
21. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909-919.
22. Alexander FE, Anderson TJ, Brown HK, et al. 14 Years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 1999;353(9168):1903-1908.
23. Berry DA, Cronin KA, Plevritis SK, et al; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
24. American Cancer Society. American Cancer Society guidelines for the early detection of cancer. http://www.cancer.org/Healthy/FindCancerEarly /CancerScreeningGuidelines/american-cancer -society-guidelines-for-the-early- detection-of -cancer. Accessed October 11, 2012.
25. US Preventive Services Task Force. Screening for breast cancer. http://www .uspreventiveservicestaskforce.org/uspstf /uspsbrca.htm. Accessed October 11, 2012.
26. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727-737; W237-W242.
27. Howard DH, Adams EK. Mammography rates after the 2009 US Preventive Services Task Force breast cancer screening recommendation. Prev Med. 2012;55(5):485-487.
28. Kerlikowske K, Hubbard RA, Miglioretti DL, et al; Breast Cancer Surveillance Consortium. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med. 2011;155(8):493-502.
29. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635-648.
30. de Koning HJ, Boer R,Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87(16):1217- 1223.
31. Hofvind S, Geller BM, Skelly J, Vacek PM. Sensitivity and specificity of mammographic screening as practiced in Vermont and Norway. Br J Radiol. 2012;85(1020):e1226-e1232.
32. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;(1):CD001877. doi:10.1002 /14651858.CD001877.pub4.
33. Hendrick RE, Helvie MA. United States Preventive Services Task Force screening mammography recommendations: science ignored. AJR AmJ Roentgenol. 2011;196(2):W112-W116.
34. Mandelblatt JS, Cronin KA, Bailey S, et al; Breast CancerWorking Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-747.
35. Centers for Disease Control and Prevention (CDC). Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(3):41-45.
36. Hoerger TJ, Ekwueme DU,Miller JW, et al. Estimated effects of the National Breast and Cervical Cancer Early Detection Program on breast cancer mortality. Am J Prev Med. 2011;40(4): 397-404.
37. Pisano ED, Gatsonis C, Hendrick E, et al; Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773-1783.
38. Granader EJ, Dwamena B, Carlos RC. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol. 2008;15(12):1590-1595.
39. Heller SL, Moy L. Imaging features and management of high-risk lesions on contrast-enhanced dynamic breast MRI. AJR AmJ Roentgenol. 2012;198(2):249-255.
40. MorrowM,Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011;378(9805):1804-1811.
41. Moon H-G, Han W, Ahn SK, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg. 2013;257(1):133-137.
42. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010;375(9714):563-571.
43. Gennaro G, Hendrick RE, Ruppel P, et al. Performance comparison of single-view digital breast tomosynthesis plus single-view digital mammography with two-view digital mammography. Eur Radiol. 2012;23(3):664-672.
44. Shin HJ, Kim HH, Cha JH, Park JH, Lee KE, Kim JH. Automated ultrasound of the breast for diagnosis: interobserver agreement on lesion detection and characterization. AJR AmJ Roentgenol. 2011;197(3):747-754.
45. Lewis JL, Lee DY, Tartter PI. The significance of lobular carcinoma in situ and atypical lobular hyperplasia of the breast. Ann Surg Oncol. 2012;19(13):4124-4128.
46. Ingegnoli A, d'Aloia C, Frattaruolo A, et al. Flat epithelial atypia and atypical ductal hyperplasia: carcinoma underestimation rate. Breast J. 2010;16(1):55-59.
47. Kohr JR, Eby PR, Allison KH, et al. Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications. Radiology. 2010;255(3):723-730.
48. Sinn H-P, Elsawaf Z, Helmchen B, Aulmann S. Early breast cancer precursor lesions: lessons learned from molecular and clinical studies. Breast Care (Basel). 2010;5(4):218-226.
49. Dillon MF, McDermott EW, Hill AD, O'Doherty A, O'Higgins N, Quinn CM. Predictive value of breast lesions of "uncertain malignant potential" and "suspicious for malignancy" determined by needle core biopsy. Ann Surg Oncol. 2007;14(2):704-711.
50. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1983;1(4):227-241.
51. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351-375.
52. Mendez A, Cabanillas F, Echenique M, Malekshamran K, Perez I, Ramos E. Mammographic features and correlation with biopsy findings using 11-gauge stereotactic vacuum-assisted breast biopsy (SVABB). Ann Oncol. 2004;15(3):450-454.
53. SilversteinMJ, Lagios MD. Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr. 2010;2010(41):193-196.
54. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;17(5):1442-1448.
55. Rakha EA, Lee AHS, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99-104.
56. Chen C-Y, Sun L-M, Anderson BO. Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer. 2006;107(7):1448-1458.
57. Yim JH, Wick MR, Philpott GW, Norton JA, Doherty GM. Underlying pathology in mammary Paget's disease. Ann Surg Oncol. 1997;4(4): 287-292.
58. Khosravi-Shahi P. Management of non metastatic phyllodes tumors of the breast: review of the literature. Surg Oncol. 2011;20(4):e143-e148.
59. TM in early-stage estrogen receptor-positive breast cancer. Oncologist. 2012;17(4):492-498.
60. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol. 2010;7(12):725-732.
61. Albain KS, Barlow WE, Shak S, et al; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
62. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(suppl 3):S141-S145.
63. Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009;9(5):417-422.
64. Bastien RR, Rodríguez-Lescure A, EbbertMT, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012;5(1):44. doi: 10.1186/1755-8794-5-44.
65. Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18(16):4465-4472.
66. Cheang MCU, Voduc KD, Tu D, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTGMA.5 randomized trial. Clin Cancer Res. 2012;18(8):2402-2412.
67. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7(6):340-347.
68. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170-178.
69. Halsted WS. The results of operation for the cure of cancer of the breast performed at John Hopkins Hospital from June 1889 to January 1894. Ann Surg. 1894;20(5):497-555.
70. McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? a 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16(10):2682-2690.
71. Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575.
72. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.
73. Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ. Optimizing the total skin-sparing mastectomy. Arch Surg. 2008;143(1):38-45.
74. Murthy V, Chamberlain RS. Defining a place for nipple-sparing mastectomy in modern breast care: an evidence based review [published online January 29, 2012]. Breast J. doi:10.1111 /j.1524-4741.2011.01220.x.
75. Jensen JA, Orringer JS, Giuliano AE. Nipple-sparing mastectomy in 99 patients with a mean follow-up of 5 years. Ann Surg Oncol. 2011;18(6):1665-1670.
76. Garcia-Etienne CA, Cody HS III, Disa JJ, Cordeiro P, Sacchini V. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J. 2009;15(4):440-449.
77. Babiera G, Simmons R. Nipple-areolar complex-sparing mastectomy: feasibility, patient selection, and technique. Ann Surg Oncol. 2010;17(suppl 3):245-248.
78. Bedrosian I, Hu C-Y, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401-409.
79. Brewster AM, Parker PA. Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist. 2011;16(7):935-941.
80. Morton DL,Wen DR,Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-399.
81. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-401.
82. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222(3):394-401.
83. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-933.
84. Van Zee KJ, Manasseh D-ME, Bevilacqua JLB, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140-1151.
85. Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg. 2009;208(2):229-235.
86. Erb KM, Julian TB. Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep.2009;11(1):15-20.
87. Deutsch M, Land S, Begovic M, Sharif S. The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys. 2008;70(4):1020-1024.
88. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575.
89. Giuliano AE,McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-433.
90. Gainer SM, Hunt KK, Beitsch P, Caudle AS, Mittendorf EA, Lucci A. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012;19(10):3152-3158.
91. Barry JM,Weber WP, Sacchini V. The evolving role of axillary lymph node dissection in the modern era of breast cancer management. Surg Oncol. 2012;21(2):143-145.
92. Lambert K, Patani N, Mokbel K. Ductal carcinoma in situ: recent advances and future prospects. Int J Surg Oncol. 2012;2012:347385. doi:10.1155/2012/ 347385.
93. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [published correction appears in J Clin Oncol. 2005;23(21):4808].
94. J Clin Oncol. 2005;23(12):2694-2702.
95. Newman EA, Sabel MS, Nees AV, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007;14(10):2946-2952.
96. Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
97. Martin M, Villar A, Sole-Calvo A, et al; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM Group. Ann Oncol. 2003;14(6):833-842.
98. Gianni L, Norton L,Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN. Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol. 2009;27(28):4798-4808.
99. Paik S, Taniyama Y, Geyer CE Jr. Anthracyclines in the treatment of HER2-negative breast cancer. J Natl Cancer Inst. 2008;100(1):2-4.
100. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.
101. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603.
102. Bowles EJA,Wellman R, Feigelson HS, et al; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293-1305.
103. Ginés J, Sabater E, Martorell C, Grau M, Monroy M, Casado MA. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol. 2011;13(7):485-498.
104. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2027.
105. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;(4):CD004421.
106. Kaufmann M, vonMinckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508-1516.
107. Bear HD, Anderson S, Brown A, et al; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-4174.
108. Vilarino-Varela M, Chin YS, Makris A. Current indications for post-mastectomy radiation. Int Semin Surg Oncol. 2009;6:5. doi: 10.1186/1477-7800-6-5.
109. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987-1001.
110. Vicini F, Beitsch P, Quiet C, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2011;79(3):808-817.
111. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91-102.
112. Khan AJ, Arthur D, Vicini F, et al. Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2012;19(5):1477-1483.
113. Goyal S, Khan AJ, Vicini F, et al. Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial breast irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2009;16(9):2450-2458.
114. McCormick B. Hypofractionated whole breast radiation and partial breast radiation for early-stage breast cancers: an update on progress. J Natl Compr Canc Netw. 2012;10(9):1161-1164.
115. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869): 805-816.
116. Howell A, Cuzick J, Baum M, et al; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
117. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7(8):1120-1128.
118. Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000;135(12):1469-1474.
119. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
120. Paik S, Kim C,Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409-1411.
121. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243. doi:10.1002 /14651858.CD006243.pub2.
122. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
123. Baselga J, Cortés J, Kim S-B, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
124. Capelan M, Pugliano L, De Azambuja E, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273-282.
125. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
126. Untch M, Loibl S, Bischoff J, et al; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135-144.
127. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221.
128. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J AmColl Cardiol. 2012;60(24):2504-2512.
129. Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular-endothelial- growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012;7:CD008941. doi:10.1002/14651858.CD008941.pub2.
130. Khatcheressian JL,Wolff AC, Smith TJ, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24(31):5091-5097.